Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 26;6(3):31.
doi: 10.3390/jcdd6030031.

Lipoprotein(a) Gene Polymorphism Increases a Risk Factor for Aortic Valve Calcification

Ugur Ozkan  1   2 , Fatih Ozcelik  1 , Mustafa Yildiz  3 , Metin Budak  4   5
Affiliations

Lipoprotein(a) Gene Polymorphism Increases a Risk Factor for Aortic Valve Calcification

Ugur Ozkan et al. J Cardiovasc Dev Dis. .

Abstract

Calcific aortic valve disease (CAVD) is a multifactorial condition. Both environmental andgenetic factors play an important role in its etiology. CAVD exhibits a broad spectrum, varying frommild valve thickening to severe valve calcification and stenosis. Progression of the disease consistsof chronic inflammation, lipoprotein deposition, and active leaflet calcification. It is a process similarto coronary artery disease. In this study, we investigated Lp(a) levels and gene polymorphismsassociated with calcific aortic stenosis from blood samples after echocardiography in the evaluationof 75 patients diagnosed with CAVD and 77 controls. Blood tests were run in our laboratory to ruleout certain risk factors before echocardiography examination. A significant association amongsmoking, elevated LDL level and creatinine, low albumin levels, Lp(a) level, rs10455872, andrs3798220 polymorphisms may be considered genetic risk factors for the development of calcificaortic stenosis.

Keywords: Lp(a) level; calcific aortic valve stenosis; rs10455872; rs3798220.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Freeman R.V., Otto C.M. Spectrum of calcific aortic valve disease: Pathogenesis, disease progression, and treatment strategies. Circulation. 2005;111:3316–3326. doi: 10.1161/CIRCULATIONAHA.104.486738. - DOI - PubMed
    1. Iung B., Vahanian A. Epidemiology of valvular heart disease in the adult. Nat. Rev. Cardiol. 2011;8:162–172. doi: 10.1038/nrcardio.2010.202. - DOI - PubMed
    1. Iung B., Baron G., Butchart E.G., Delahaye F., Gohlke-Barwolf C., Levang O.W., Tornos P., Vanoverschelde J.L., Vermeer F., Boersma E., et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur. Heart J. 2003;24:1231–1243. doi: 10.1016/S0195-668X(03)00201-X. - DOI - PubMed
    1. Sipahi T., Basak A.A., Ozgen Z., Aksoy A., Omurlu I.K., Palabiyik O., Cakina S., Sener S. Lack of Evidence for Contribution of Endothelial Nitric Oxide Synthase Intron 4 Vntr Gene Polymorphisms to Development of Ischemic Stroke in Turkish Subjects. Biotechnol. Biotechnol. Equip. 2009;23:1372–1377. doi: 10.1080/13102818.2009.10817673. - DOI
    1. Li C., Xu S., Gotlieb A.I. The response to valve injury. A paradigm to understand the pathogenesis of heart valve disease. Cardiovasc. Pathol. 2011;20:183–190. doi: 10.1016/j.carpath.2010.09.008. - DOI - PubMed

LinkOut - more resources